NCT04745832 2024-11-04Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)MEI Pharma, Inc.Phase 3 Terminated82 enrolled 11 charts
NCT00088881 2017-05-25Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaNational Cancer Institute (NCI)Phase 2 Terminated62 enrolled 8 charts